Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
Abstract Introduction In recent years, enzalutamide and abiraterone have been widely used as treatments for metastatic castration-resistant prostate cancer (mCRPC). However, the cost-effectiveness of these drugs in Iran is unknown. This study evaluated the cost-effectiveness of enzalutamide for the...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2024-02-01
|
| Serija: | BMC Urology |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12894-024-01431-w |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|